These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 28611859)

  • 1. Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus.
    Kawata T; Iizuka T; Iemitsu K; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyanagi S; Hoshino K; Ishikawa M; Matsuzawa Y; Obana M; Sasai N; Kaneshige H; Minagawa F; Saito T; Shinoda K; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2017 Jul; 9(7):586-595. PubMed ID: 28611859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial.
    Inoue H; Morino K; Ugi S; Tanaka-Mizuno S; Fuse K; Miyazawa I; Kondo K; Sato D; Ohashi N; Ida S; Sekine O; Yoshimura M; Murata K; Miura K; Arima H; Maegawa H;
    J Diabetes Investig; 2019 Jul; 10(4):1012-1021. PubMed ID: 30536746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of ipragliflozin as monotherapy or as add-on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics.
    Osonoi T; Nakamoto S; Saito M; Tamasawa A; Ishida H; Osonoi Y
    J Diabetes Investig; 2018 Mar; 9(2):341-353. PubMed ID: 28644562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.
    Iizuka T; Iemitsu K; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Kawata T; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyagi S; Hoshino K; Ishikawa M; Matsuzawa Y; Obana M; Sasai N; Kaneshige H; Minagawa F; Saito T; Shinoda K; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2016 Feb; 8(2):116-25. PubMed ID: 26767080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study.
    Iemitsu K; Kawata T; Iizuka T; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyanagi S; Hoshino K; Ishikawa M; Matsuzawa Y; Obana M; Sasai N; Kaneshige H; Minagawa F; Saito T; Shinoda K; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2017 Sep; 9(9):793-801. PubMed ID: 28811858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
    Nomiyama T; Shimono D; Horikawa T; Fujimura Y; Ohsako T; Terawaki Y; Fukuda T; Motonaga R; Tanabe M; Yanase T;
    Endocr J; 2018 Aug; 65(8):859-867. PubMed ID: 29806620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats.
    Takasu T; Hayashizaki Y; Hirosumi J; Minoura H; Amino N; Kurosaki E; Takakura S
    Biol Pharm Bull; 2017; 40(5):675-680. PubMed ID: 28458353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study.
    Iemitsu K; Iizuka T; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Kawata T; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyagi S; Hoshino K; Ishikawa M; Obana M; Sasai N; Kaneshige H; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2016 May; 8(5):373-8. PubMed ID: 27081422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus.
    Kashiwagi A; Kazuta K; Yoshida S; Nagase I
    J Diabetes Investig; 2014 Jul; 5(4):382-91. PubMed ID: 25411597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes receiving conventional therapy: clinical implication of the importance of exercise habits during treatment with ipragliflozin.
    Kato M; Sakai K; Saito K; Tsutsui K; Yamashita S; Kato N
    Diabetol Int; 2017 Aug; 8(3):275-285. PubMed ID: 30603333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolomic analysis of serum samples from a clinical study on ipragliflozin and metformin treatment in Japanese patients with type 2 diabetes: Exploring human metabolites associated with visceral fat reduction.
    Tsukagoshi-Yamaguchi A; Koshizaka M; Ishibashi R; Ishikawa K; Ishikawa T; Shoji M; Ide S; Ide K; Baba Y; Terayama R; Hattori A; Takemoto M; Ouchi Y; Maezawa Y; Yokote K;
    Pharmacotherapy; 2023 Dec; 43(12):1317-1326. PubMed ID: 37772313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study.
    Ishihara H; Yamaguchi S; Nakao I; Sakatani T
    Diabetes Ther; 2018 Aug; 9(4):1549-1567. PubMed ID: 29926400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial.
    Min KW; Ku BJ; Lee JH; Kim MS; Ahn KJ; Lee MK; Kokubo S; Yoshida S; Cho HJ; Cha BS
    Diabetes Metab J; 2017 Apr; 41(2):135-145. PubMed ID: 28447440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Ipragliflozin on Postprandial Glucose Metabolism and Gut Peptides in Type 2 Diabetes: A Pilot Study.
    Ueno H; Nakazato H; Ebihara E; Noma K; Kawano T; Nagamine K; Sakoda H; Nakazato M
    Diabetes Ther; 2018 Feb; 9(1):403-411. PubMed ID: 29322485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differing Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Ipragliflozin on the Decrease of Fat Mass vs. Lean Mass in Patients With or Without Metformin Therapy.
    Nagai Y; Fukuda H; Kawanabe S; Nakagawa T; Ohta A; Tanaka Y
    J Clin Med Res; 2019 Apr; 11(4):297-300. PubMed ID: 30937121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: 104-Week Follow-up of an Open-Label Study.
    Ito D; Inoue K; Sumita T; Hamaguchi K; Kaneko K; Yanagisawa M; Inukai K; Inoue I; Noda M; Shimada A
    J Clin Med Res; 2018 Sep; 10(9):679-687. PubMed ID: 30116437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats.
    Yokono M; Takasu T; Hayashizaki Y; Mitsuoka K; Kihara R; Muramatsu Y; Miyoshi S; Tahara A; Kurosaki E; Li Q; Tomiyama H; Sasamata M; Shibasaki M; Uchiyama Y
    Eur J Pharmacol; 2014 Mar; 727():66-74. PubMed ID: 24486393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.
    Ohkura T
    World J Diabetes; 2015 Feb; 6(1):136-44. PubMed ID: 25685284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes.
    Ohta A; Kato H; Ishii S; Sasaki Y; Nakamura Y; Nakagawa T; Nagai Y; Tanaka Y
    Expert Opin Pharmacother; 2017 Oct; 18(14):1433-1438. PubMed ID: 28770629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
    Komiya C; Tsuchiya K; Shiba K; Miyachi Y; Furuke S; Shimazu N; Yamaguchi S; Kanno K; Ogawa Y
    PLoS One; 2016; 11(3):e0151511. PubMed ID: 26977813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.